Omics Lab Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenetics), By Frequency Of Service (One-Off, Repeat, Continuous), By Business (Hospitals, Research Institutes, Diagnostic Labs), By End Use (Cancer, Pharmaco, Reproductive, Other Genetic Disease), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 72.88 Billion
CAGR (2026-2031)	9.91%
Fastest Growing Segment	Repeat
Largest Market	North America
Market Size (2031)	USD 128.48 Billion

Market Overview

The Global Omics Lab Services Market will grow from USD 72.88 Billion in 2025 to USD 128.48 Billion by 2031 at a 9.91% CAGR. Omics lab services encompass specialized contract research and diagnostic solutions, including genomics, proteomics, and metabolomics, utilized to support pharmaceutical development and clinical diagnostics. The market is primarily propelled by the escalating prevalence of chronic diseases which fuels the demand for personalized medicine and precise molecular profiling. Furthermore, the strategic shift of biopharmaceutical companies towards outsourcing research to leverage external expertise and reduce fixed costs significantly supports sector expansion. According to the American Cancer Society, in 2025, an estimated 2,041,910 new cancer diagnoses are projected in the United States, illustrating the substantial disease burden necessitating these advanced diagnostic services.

However, a significant challenge impeding market expansion is the complex regulatory landscape regarding data privacy and ethical compliance. The management of massive datasets containing sensitive genetic information requires strict adherence to evolving international standards, imposing high operational costs and liability risks on laboratories. These stringent requirements can delay project timelines and create barriers to entry for new service providers, thereby slowing the overall pace of market innovation and accessibility.

Key Market Drivers

The rising adoption of personalized and precision medicine is a primary force propelling the Global Omics Lab Services Market, as healthcare providers increasingly rely on molecular profiling to tailor therapeutic interventions. This paradigm shift from empirical prescribing to targeted therapies necessitates comprehensive genomic, proteomic, and metabolomic analyses, directly increasing the volume of samples processed by specialized laboratories. Pharmaceutical companies are heavily investing in biomarker discovery to support these targeted treatments, thereby driving demand for outsourced high-complexity testing to ensure clinical efficacy and regulatory compliance. According to the Personalized Medicine Coalition, May 2025, in the 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024' report, the FDA approved 18 new personalized medicines in 2024, which accounted for approximately 38% of all newly approved therapeutic molecular entities, underscoring the critical dependence of modern drug development on advanced omics data.

Simultaneously, the growing demand for liquid biopsy and non-invasive diagnostics is significantly expanding the addressable market for omics laboratories by enabling frequent disease monitoring without the procedural risks associated with tissue biopsies. This trend forces service providers to scale their sequencing capabilities and bioinformatic infrastructure to handle the influx of complex blood-based biomarker testing required for oncology surveillance and early detection. According to Guardant Health, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported a volume of approximately 206,700 oncology clinical tests for the full year 2024, representing a year-over-year increase of 20%. The broader financial scale of this diagnostic shift is further evidenced as, according to Exact Sciences, in 2025, the company generated total revenue of $2.76 billion for the full year 2024, driven largely by the robust adoption of its cancer screening and diagnostic test services.

Download Free Sample Report

Key Market Challenges

The complex regulatory landscape regarding data privacy and ethical compliance stands as a critical impediment to the growth of the Global Omics Lab Services Market. As laboratories process massive volumes of sensitive genetic information, they are compelled to establish sophisticated data protection infrastructures to meet rigorous international standards. This mandatory resource allocation significantly inflates operational expenditures and diverts capital from research and development, causing substantial delays in project timelines. The financial and technical burden of these compliance measures effectively creates a high barrier to entry, discouraging smaller, innovative entities from entering the sector and consolidating market power among fewer, larger providers.

Furthermore, the severe financial consequences of potential data breaches compel laboratories to prioritize risk aversion over service expansion. The costs associated with data security failures are prohibitive and constitute a major liability risk. According to the American Hospital Association's 2025 Environmental Scan report, in 2024, the average cost of a healthcare data breach was $9.77 million. Such elevated liability risks force organizations to implement restrictive data handling protocols that slow the pace of collaborative research and ultimately hamper the market’s ability to deliver timely, accessible diagnostic solutions.

Key Market Trends

The Integration of Artificial Intelligence for Advanced Data Interpretation is swiftly becoming a foundational trend in the omics lab services sector, fundamentally changing how laboratories deliver value beyond raw sequencing data. Service providers are increasingly embedding machine learning algorithms directly into their bioinformatics pipelines to decipher complex multi-omics datasets, thereby allowing pharmaceutical clients to identify novel therapeutic targets with unprecedented speed and accuracy. This transition from simple data generation to AI-driven insight generation has created a lucrative revenue stream for tech-enabled laboratories. According to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported a total revenue of $693.4 million for the fiscal year 2024, representing a 30.4% year-over-year growth that was significantly bolstered by the expansion of its AI-enabled data and services capabilities.

Simultaneously, the Emergence of Spatial Omics and Tissue Profiling Technologies is redefining the analysis of biological systems by enabling researchers to map gene expression within the physical context of tissue architecture. Unlike traditional bulk or single-cell sequencing which dissociates cells, spatial profiling preserves the locational integrity of the sample, providing critical insights into the tumor microenvironment and cellular interactions that are essential for immuno-oncology research. This technological leap has spurred laboratories to invest heavily in high-plex imaging and spatially resolved transcriptomics platforms to meet the surging demand from biopharma developers. According to 10x Genomics, January 2025, in the 'Preliminary Select Fourth Quarter and Full Year 2024 Results', the company generated approximately $121.1 million in spatial consumables revenue for the full year 2024, highlighting the rapid industrial adoption of these context-aware profiling solutions.

Segmental Insights

Based on the segmentation by frequency of service, the Repeat segment is identified as the fastest-growing category in the Global Omics Lab Services Market. This accelerated expansion is primarily driven by the fundamental shift in personalized medicine from single-point diagnosis to longitudinal patient monitoring. As the management of chronic conditions such as cancer increasingly relies on surveillance to track disease progression and therapeutic efficacy, the demand for recurrent testing has surged. Consequently, healthcare providers are prioritizing repeat omics analysis to ensure early detection of recurrence and to adjust treatment strategies dynamically over time.

Regional Insights

North America maintains a dominant position in the Global Omics Lab Services Market due to substantial investments in genomic research and a robust pharmaceutical industry. This leadership is supported by extensive government funding from institutions such as the National Institutes of Health, which fosters innovation in personalized medicine and drug discovery. Additionally, the region benefits from established healthcare infrastructure and favorable regulatory guidelines from the U.S. Food and Drug Administration. These factors collectively drive the widespread adoption of transcriptomics, proteomics, and metabolomics services for clinical and research applications.

Recent Developments

• In August 2024, Illumina, Inc. announced a new research partnership with the Broad Institute of MIT and Harvard to advance the field of single-cell sequencing. This collaboration focuses on leveraging Illumina’s Fluent technology to develop and validate new kits aimed at catalyzing large-scale CRISPR screening experiments. The partnership seeks to accelerate the adoption of high-capacity single-cell experiments, enabling researchers to generate multi-omics data at an unprecedented scale. By combining the institute's scientific expertise with the company's innovative sequencing platforms, the initiative aims to drive deeper biological insights and redefine the capabilities of genomic research for drug discovery and development.
• In July 2024, Thermo Fisher Scientific Inc. completed its acquisition of Olink Holding AB, a leading provider of next-generation proteomics solutions. The transaction, valued at approximately $3.1 billion, integrated Olink’s proprietary Proximity Extension Assay technology into Thermo Fisher’s Life Sciences Solutions segment. This strategic move was intended to bolster the company’s capabilities in the high-growth proteomics market, complementing its existing mass spectrometry and analytical offerings. The acquisition enables the company to empower scientists with advanced tools for protein biomarker discovery and precision medicine, facilitating a deeper understanding of human biology and accelerating the development of new therapies.
• In May 2024, Azenta, Inc. officially opened a new state-of-the-art genomics laboratory in Oxford, United Kingdom, to expand the global footprint of its GENEWIZ Multiomics and Synthesis Solutions business. This facility was established to provide UK-based researchers with local access to advanced next-generation sequencing platforms and the expertise of a dedicated scientific team. The laboratory features cutting-edge technology, including high-throughput sequencing systems, to support critical research in fields such as infectious diseases and oncology. This expansion underscores the company’s commitment to delivering high-quality data and faster turnaround times for the European scientific community.
• In January 2024, Standard BioTools Inc. announced the completion of its merger with SomaLogic, establishing a diversified leader in the life sciences tools sector. This strategic combination integrated SomaLogic’s differentiated proteomics platform with Standard BioTools’ mass cytometry and microfluidics technologies, creating a robust portfolio of multi-omics solutions for research. The merged entity aims to accelerate breakthroughs in human health by providing scaled and complementary offerings to laboratory professionals and researchers globally. The transaction was designed to enhance financial flexibility and expedite the company’s path to profitability while expanding its commercial reach in the evolving omics market.

Key Market Players

• Agilent Technologies, Inc.
• Q2 Solutions LLC
• Flomics Biotech
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Illumina, Inc
• Quest Diagnostics Incorporated
• Phenoswitch Bioscience Inc.
• Spectrus Corporation

By Service	By Frequency Of Service	By Business	By End Use	By Region
Genomics Proteomics Transcriptomics Metabolomics Epigenetics	One-Off Repeat Continuous	Hospitals Research Institutes Diagnostic Labs	Cancer Pharmaco Reproductive Other Genetic Disease	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Omics Lab Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Omics Lab Services Market, By Service:

• Genomics
• Proteomics
• Transcriptomics
• Metabolomics
• Epigenetics

• Omics Lab Services Market, By Frequency Of Service:

• One-Off
• Repeat
• Continuous

• Omics Lab Services Market, By Business:

• Hospitals
• Research Institutes
• Diagnostic Labs

• Omics Lab Services Market, By End Use:

• Cancer
• Pharmaco
• Reproductive
• Other Genetic Disease

• Omics Lab Services Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE